Loading clinical trials...
Loading clinical trials...
Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients
Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.
Age
60 - No limit years
Sex
ALL
Healthy Volunteers
No
ProMedica Toledo Hospital
Toledo, Ohio, United States
Start Date
August 30, 2017
Primary Completion Date
July 1, 2026
Completion Date
September 1, 2026
Last Updated
August 7, 2025
200
ESTIMATED participants
Tranexamic Acid (TXA)
DRUG
Saline solution
DRUG
Lead Sponsor
Gregory M Georgiadis MD
NCT06565910
NCT07432737
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06521671